Costs and cost-effectiveness of a collaborative data-to-care intervention for HIV treatment and care in the United States

被引:1
|
作者
Shrestha, Ram K. [1 ,2 ]
Fanfair, Robyn Neblett [2 ]
Randall, Liisa M. [3 ]
Lucas, Crystal [4 ]
Nichols, Lisa [5 ]
Camp, Nasima [2 ]
Brady, Kathleen A. [4 ]
Jenkins, Heidi [6 ]
Altice, Frederick L. [5 ]
DeMaria, Alfred [3 ]
Villanueva, Merceditas [5 ]
Weidle, Paul J. [2 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd MS E 45, Atlanta, GA 30329 USA
[2] Ctr Dis Control & Prevent, Div HIV Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA
[3] Massachusetts Dept Publ Hlth, Boston, MA USA
[4] Philadelphia Dept Publ Hlth, Philadelphia, PA USA
[5] Yale Univ, Sch Med, New Haven, CT USA
[6] Connecticut Dept Publ Hlth, Hartford, CT USA
关键词
HIV surveillance; data-to-care; re-engagement; randomized controlled trial; economic evaluation; cost-effectiveness;
D O I
10.1002/jia2.26040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionData-to-care programmes utilize surveillance data to identify persons who are out of HIV care, re-engage them in care and improve HIV care outcomes. We assess the costs and cost-effectiveness of re-engagement in an HIV care intervention in the United States. MethodsThe Cooperative Re-engagement Control Trial (CoRECT) employed a data-to-care collaborative model between health departments and HIV care providers, August 2016-July 2018. The health departments in Connecticut (CT), Massachusetts (MA) and Philadelphia (PHL) collaborated with HIV clinics to identify newly out-of-care patients and randomize them to receive usual linkage and engagement in care services (standard-of-care control arm) or health department-initiated active re-engagement services (intervention arm). We used a microcosting approach to identify the activities and resources involved in the CoRECT intervention, separate from the standard-of-care, and quantified the costs. The cost data were collected at the start-up and recurrent phases of the trial to incorporate potential variation in the intervention costs. The costs were estimated from the healthcare provider perspective. ResultsThe CoRECT trial in CT, MA and PHL randomly assigned on average 327, 316 and 305 participants per year either to the intervention arm (n = 166, 159 and 155) or the standard-of-care arm (n = 161, 157 and 150), respectively. Of those randomized, the number of participants re-engaged in care within 90 days in the intervention and standard-of-care arms was 85 and 70 in CT, 84 and 70 in MA, and 98 and 67 in PHL. The additional number of participants re-engaged in care in the intervention arm compared with those in the standard-of-care arm was 15 (CT), 14 (MA) and 31 (PHL). We estimated the annual total cost of the CoRECT intervention at $490,040 in CT, $473,297 in MA and $439,237 in PHL. The average cost per participant enrolled was $2952, $2977 and $2834 and the average cost per participant re-engaged in care was $5765, $5634 and $4482. We estimated an incremental cost per participant re-engaged in care at $32,669 (CT), $33,807 (MA) and $14,169 (PHL). ConclusionsThe costs of the CoRECT intervention that identified newly out-of-care patients and re-engaged them in HIV care are comparable with other similar interventions, suggesting a potential for its cost-effectiveness in the US context.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States
    Stacey Kowal
    Eliza Kruger
    Pinar Bilir
    James H. Holmes
    William Hickerson
    Kevin Foster
    Scott Nystrom
    Jeremiah Sparks
    Narayan Iyer
    Katie Bush
    Andrew Quick
    Advances in Therapy, 2019, 36 : 1715 - 1729
  • [22] Managed care and systems cost-effectiveness -: Treatment for depression
    Alegría, M
    Frank, R
    McGuire, T
    MEDICAL CARE, 2005, 43 (12) : 1225 - 1233
  • [23] Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States
    Kowal, Stacey
    Kruger, Eliza
    Bilir, Pinar
    Holmes, James H.
    Hickerson, William
    Foster, Kevin
    Nystrom, Scott
    Sparks, Jeremiah
    Iyer, Narayan
    Bush, Katie
    Quick, Andrew
    ADVANCES IN THERAPY, 2019, 36 (07) : 1715 - 1729
  • [24] HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care?
    Hyle, Emily P.
    Naidoo, Kogieleum
    Su, Amanda E.
    El-Sadr, Wafaa M.
    Freedberg, Kenneth A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 : S87 - S95
  • [25] Cost-effectiveness of a quality improvement collaborative for obstetric and newborn care in Niger
    Broughton, Edward
    Saley, Zakari
    Boucar, Maina
    Alagane, Dondi
    Hill, Kathleen
    Marafa, Aicha
    Asma, Yaroh
    Sani, Karimou
    INTERNATIONAL JOURNAL OF HEALTH CARE QUALITY ASSURANCE, 2013, 26 (03) : 250 - +
  • [26] Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness
    Celano, Christopher M.
    Healy, Brian
    Suarez, Laura
    Levy, Douglas E.
    Mastromauro, Carol
    Januzzi, James L.
    Huffman, Jeff C.
    VALUE IN HEALTH, 2016, 19 (02) : 185 - 191
  • [27] The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States
    Tremblay, Gabriel
    Dolph, Mike
    Roy, Anuja Nidumolu
    Said, Qayyim
    Forsythe, Anna
    CLINICAL THERAPEUTICS, 2020, 42 (05) : 860 - +
  • [28] Schizophrenia costs and treatment cost-effectiveness
    Knapp, M
    ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 : 15 - 18
  • [29] The effectiveness and cost-effectiveness of shared care: protocol for a realist review
    Hardwick, Rebecca
    Pearson, Mark
    Byng, Richard
    Anderson, Rob
    SYSTEMATIC REVIEWS, 2013, 2 : 12
  • [30] A review of the cost-effectiveness of interventions to prevent sexual transmission of HIV in the United States
    Pinkerton S.D.
    Johnson-Masotti A.P.
    Holtgrave D.R.
    Farnham P.G.
    AIDS and Behavior, 2002, 6 (1) : 15 - 31